Base de dados : MEDLINE
Pesquisa : E02.319.267.120.805 [Categoria DeCS]
Referências encontradas : 681 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 69 ir para página                         

  1 / 681 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:29377953
[Au] Autor:Waduthantri S; Zhou L; Chee SP
[Ad] Endereço:Singapore Eye Research Institute, Singapore, Singapore.
[Ti] Título:Intra-cameral level of ganciclovir gel, 0.15% following topical application for cytomegalovirus anterior segment infection: A pilot study.
[So] Source:PLoS One;13(1):e0191850, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To investigate the intra-cameral level of ganciclovir following topical application of ganciclovir gel, 0.15% for cytomegalovirus (CMV) anterior segment infection. DESIGN: Non-randomized, prospective, interventional clinical study. METHODS: Patients with active CMV anterior segment infection seen at Singapore National Eye Centre, confirmed by positive CMV real time PCR (RT-PCR) of the aqueous humor, that had not been treated with any form of ganciclovir in the preceding 1 month were recruited. They were treated with ganciclovir gel, 0.15% 1cc 5 times a day. Following 6 weeks of treatment, CMV load in the aqueous humor was measured using CMV RT-PCR and the ganciclovir drug levels in tears and aqueous humor were measured using high-performance liquid chromatography-mass spectrometry. The clinical features of the disease activity and the central corneal thickness (CCT) were recorded at the baseline and post-treatment. RESULTS: There were 29 eyes of 29 patients, of which 23 eyes had CMV anterior uveitis and 6 eyes had CMV endotheliitis. At the end of week 6, 26 eyes had undetectable CMV titre in the aqueous humor and no anterior chamber (AC) activity. Two patients had an increased CMV titre and increased AC inflammation. Both of these patients were non-compliant with the treatment. One patient had a reduced CMV titre in the aqueous humor with minimal AC inflammation. The mean ganciclovir concentration in the aqueous humor and the tears were 17.4 ± 30.6 ng/ml and 20,420.9 ± 33,120.8 ng/ml respectively. Mean CCT was 552.2 ± 42.3 microns. There was a weak correlation between the ganciclovir concentration in the aqueous humor and CCT (Spearmen's r = + 0.42, p = 0.025). There was no significant correlation between the ganiclovir concentration in the tears and CCT (Spearmen's r = + 0.39, p = 0.11). CONCLUSION: Ganciclovir levels in the aqueous humor was below the 50% inhibitory dose (ID50) for CMV replication, following topical application of the ganciclovir gel, 0.15%. TRIAL REGISTRATION: SingHealth Centralized Institutional Review Board, Singapore; R733/17/2010, ClinicalTrials.gov; NCT01647529.
[Mh] Termos MeSH primário: Segmento Anterior do Olho/patologia
Antivirais/administração & dosagem
Infecções por Citomegalovirus/tratamento farmacológico
Ganciclovir/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oftálmica
Adulto
Idoso
Idoso de 80 Anos ou mais
Cromatografia Líquida
Citomegalovirus/genética
Feminino
Seres Humanos
Masculino
Meia-Idade
Projetos Piloto
Estudos Prospectivos
Reação em Cadeia da Polimerase em Tempo Real
Espectrometria de Massas em Tandem
[Pt] Tipo de publicação:CLINICAL STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antiviral Agents); P9G3CKZ4P5 (Ganciclovir)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191850


  2 / 681 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29422755
[Au] Autor:Maharana PK; Raghuwanshi S; Chauhan AK; Rai VG; Pattebahadur R
[Ad] Endereço:Department of Ophthalmology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.
[Ti] Título:Comparison of the Efficacy of Carboxymethylcellulose 0.5%, Hydroxypropyl-guar Containing Polyethylene Glycol 400/Propylene Glycol, and Hydroxypropyl Methyl Cellulose 0.3% Tear Substitutes in Improving Ocular Surface Disease Index in Cases of Dry Eye.
[So] Source:Middle East Afr J Ophthalmol;24(4):202-206, 2017 Oct-Dec.
[Is] ISSN:0975-1599
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To compare the efficacy of carboxymethylcellulose 0.5% (CMC), hydroxypropyl-guar containing polyethylene glycol 400/propylene glycol (PEG/PG), and hydroxypropyl methylcellulose 0.3% (HPMC) as tear substitutes in patients with dry eye. METHODS: A retrospective evaluation of cases presenting with symptoms of dry eye from July 2014 to June 2015 was done. Patients with Ocular Surface Disease Index (OSDI) scoring >12 were included in the study. Parameters such as age, gender, Schirmer test (ST), and tear film breakup time (TBUT) were recorded on day 0, week 1, and week 4. For analysis, cases were divided into three groups; Group 1 - CMC, Group 2 - PEG/PG, and Group 3 - HPMC. RESULTS: Overall, 120 patients were included in the study. Demographic data and baseline characteristics were comparable among the groups. Group 2 had significant improvement in percentage change in OSDI (weeks 0-1, 0-4, and 1-4, = 0.00), TBUT (weeks 0-1, = 0.01; 0-4, = 0.006; and 1-4, = 0.007), and in ST (weeks 0-1, = 0.02; 0-4, = 0.002; and 1-4, = 0.008) compared to Group 1 at all follow-ups. Group 3 had improvements similar to Group 2, but it was not at all follow-ups (improvement in percentage change OSDI [weeks 0-1, 0-4, and 1-4, = 0.00], TBUT [weeks 0-1, = 0.10; 0-4, = 0.03; and 1-4, = 0.04], and in ST [weeks 0-1, = 0.007; 0-4, = 0.03; and 1-4, = 0.12]). No significant difference was found between Groups 2 and 3. CONCLUSIONS: Hydroxypropyl-guar containing PEG/PG and HPMC as tear substitutes are better than CMC. While HPMC was comparable to PEG/PG in subjective improvement, the objective improvement was not consistent.
[Mh] Termos MeSH primário: Carboximetilcelulose Sódica/administração & dosagem
Síndromes do Olho Seco/tratamento farmacológico
Derivados da Hipromelose/administração & dosagem
Lubrificantes Oftálmicos/administração & dosagem
Polissacarídeos/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oftálmica
Adulto
Combinação de Medicamentos
Síndromes do Olho Seco/fisiopatologia
Feminino
Seres Humanos
Masculino
Meia-Idade
Soluções Oftálmicas
Polietilenoglicóis/química
Polissacarídeos/química
Propilenoglicol/química
Estudos Retrospectivos
Lágrimas/fisiologia
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Lubricant Eye Drops); 0 (Ophthalmic Solutions); 0 (Polysaccharides); 0 (hydroxypropyl guar); 30IQX730WE (Polyethylene Glycols); 3NXW29V3WO (Hypromellose Derivatives); 6DC9Q167V3 (Propylene Glycol); B697894SGQ (polyethylene glycol 400); K679OBS311 (Carboxymethylcellulose Sodium)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180210
[St] Status:MEDLINE
[do] DOI:10.4103/meajo.MEAJO_165_15


  3 / 681 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29279557
[Au] Autor:Kaneko T; Arai M; Watanabe A; Tsuruoka S
[Ad] Endereço:Divisions of Nephrology, Nippon Medical School Tama Nagayama Hospital.
[Ti] Título:Effectiveness of Measuring Genetic Polymorphisms in Metabolizing Enzymes of Tacrolimus within One Medical Facility.
[So] Source:J Nippon Med Sch;84(6):274-279, 2017.
[Is] ISSN:1347-3409
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Because genetic polymorphisms cause diverse activity in drug metabolizing enzymes, drug concentrations in the blood may be variable among patients. We analyzed the genotypes of CYP3A5 and MDR1, and investigated their relationship with whole blood drug concentrations. METHODS: Eight patients were administered an oral dose of tacrolimus for one week or longer prior to enrollment in this study. Whole blood concentrations for tacrolimus were measured 12 hours post oral administration, on the same day as genotyping, within our hospital using a fully automated gene analyzer. The procedures became so rapid that collection of blood samples could be completed within the same day (approximately one hour). RESULTS: The genotype frequency of CYP3A5 was 3/ 3 in five patients, 1/ 3 in two patients, and 1/ 1 in one patient. All five patients with 3/ 3 showed favorable increases in tacrolimus blood concentrations. In the two patients with 1/ 3, an increase in tacrolimus blood concentration was not readily achieved in one patient, but increased favorably in the other patient. In the patient with 1/ 1, tacrolimus was not detectable in the patient's blood. A favorable treatment effect was obtained by changing tacrolimus to cyclosporine. It is notable that genotypes in patients where tacrolimus was not detected in the blood were wild types: 2677G/G and 3435C/C in MDR1. CONCLUSIONS: The measurement of genetic polymorphisms in metabolizing enzymes of tacrolimus, within one medical facility, is applicable for the selection of immunosuppressants and individual dosing for the treatment of autoimmune disease.
[Mh] Termos MeSH primário: Citocromo P-450 CYP3A/genética
Genótipo
Imunossupressores/sangue
Polimorfismo Genético/genética
Tacrolimo/sangue
[Mh] Termos MeSH secundário: Subfamília B de Transportador de Cassetes de Ligação de ATP/genética
Administração Oftálmica
Adolescente
Adulto
Idoso
Doenças Autoimunes/tratamento farmacológico
Feminino
Seres Humanos
Imunossupressores/metabolismo
Masculino
Meia-Idade
Medicina de Precisão
Tacrolimo/administração & dosagem
Tacrolimo/metabolismo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ABCB1 protein, human); 0 (ATP Binding Cassette Transporter, Sub-Family B); 0 (Immunosuppressive Agents); EC 1.14.14.1 (Cytochrome P-450 CYP3A); WM0HAQ4WNM (Tacrolimus)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171228
[St] Status:MEDLINE
[do] DOI:10.1272/jnms.84.274


  4 / 681 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28458352
[Au] Autor:Matsuda T; Hiraoka S; Urashima H; Ogura A; Ishida T
[Ad] Endereço:Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University.
[Ti] Título:Preparation of an Ultrafine Rebamipide Ophthalmic Suspension with High Transparency.
[So] Source:Biol Pharm Bull;40(5):665-674, 2017.
[Is] ISSN:1347-5215
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:A 2% commercially available, milky-white, rebamipide micro-particle suspension is used to treat dry eyes, and it causes short-term blurring of the patient's vision. In the current study, to improve the transparency of a rebamipide suspension, we attempted to obtain a clear rebamipide suspension by transforming the rebamipide particles to an ultrafine state. In the initial few efforts, various rebamipide suspensions were prepared using a neutralizing crystallization method with additives, but the suspensions retained their opaque quality. However, as a consequence of several critical improvements in the neutralizing crystallization methods such as selection of additives for crystallization, process parameters during crystallization, the dispersion method, and dialysis, we obtained an ultrafine rebamipide suspension (2%) that was highly transparent (transmittance at 640 nm: 59%). The particle size and transparency demonstrated the fewest level of changes at 25°C after 3 years, compared to initial levels. During that period, no obvious particle sedimentation was observed. The administration of this ultrafine rebamipide suspension (2%) increased the conjunctival mucin, which was comparable to the commercially available micro-particle suspension (2%). The corneal and conjunctival concentration of rebamipide following ocular administration of the ultrafine suspension was slightly higher than that of the micro-particle suspension. The ultrafine rebamipide suspension (eye-drop formulation) with a highly transparent ophthalmic clearness should improve a patient's QOL by preventing even a shortened period of blurred vision.
[Mh] Termos MeSH primário: Alanina/análogos & derivados
Antiulcerosos/administração & dosagem
Antiulcerosos/química
Soluções Oftálmicas/química
Quinolonas/administração & dosagem
Quinolonas/química
[Mh] Termos MeSH secundário: Administração Oftálmica
Alanina/administração & dosagem
Alanina/química
Animais
Túnica Conjuntiva/efeitos dos fármacos
Túnica Conjuntiva/metabolismo
Córnea/efeitos dos fármacos
Córnea/metabolismo
Cristalização
Diálise
Masculino
Mucinas/metabolismo
Tamanho da Partícula
Coelhos
Suspensões
Difração de Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Ulcer Agents); 0 (Mucins); 0 (Ophthalmic Solutions); 0 (Quinolones); 0 (Suspensions); LR583V32ZR (rebamipide); OF5P57N2ZX (Alanine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1248/bpb.b16-00962


  5 / 681 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27775976
[Au] Autor:Grey KR; Warshaw EM
[Ad] Endereço:From the *University of Minnesota Medical School; †HCMC Parkside Occupational and Contact Dermatitis Clinic; ‡Department of Dermatology, Minneapolis Veterans Affairs Medical Center; and §Department of Dermatology, University of Minnesota Medical School, Minneapolis.
[Ti] Título:Allergic Contact Dermatitis to Ophthalmic Medications: Relevant Allergens and Alternative Testing Methods.
[So] Source:Dermatitis;27(6):333-347, 2016 Nov/Dec.
[Is] ISSN:2162-5220
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Allergic contact dermatitis is an important cause of periorbital dermatitis. Topical ophthalmic agents are relevant sensitizers. Contact dermatitis to ophthalmic medications can be challenging to diagnose and manage given the numerous possible offending agents, including both active and inactive ingredients. Furthermore, a substantial body of literature reports false-negative patch test results to ophthalmic agents. Subsequently, numerous alternative testing methods have been described. This review outlines the periorbital manifestations, causative agents, and alternative testing methods of allergic contact dermatitis to ophthalmic medications.
[Mh] Termos MeSH primário: Dermatite Alérgica de Contato/etiologia
Dermatoses Faciais/etiologia
Lubrificantes Oftálmicos/efeitos adversos
Soluções Oftálmicas/efeitos adversos
[Mh] Termos MeSH secundário: Administração Oftálmica
Agonistas de Receptores Adrenérgicos alfa 1/efeitos adversos
Antagonistas Adrenérgicos beta/efeitos adversos
Antibacterianos/efeitos adversos
Anti-Infecciosos Locais/efeitos adversos
Anti-Inflamatórios/efeitos adversos
Antineoplásicos/efeitos adversos
Antivirais/efeitos adversos
Inibidores da Anidrase Carbônica/efeitos adversos
Antagonistas Colinérgicos/efeitos adversos
Glaucoma/tratamento farmacológico
Antagonistas dos Receptores Histamínicos/efeitos adversos
Seres Humanos
Agonistas Muscarínicos/efeitos adversos
Antagonistas Muscarínicos/efeitos adversos
Prostaglandinas Sintéticas/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenergic alpha-1 Receptor Agonists); 0 (Adrenergic beta-Antagonists); 0 (Anti-Bacterial Agents); 0 (Anti-Infective Agents, Local); 0 (Anti-Inflammatory Agents); 0 (Antineoplastic Agents); 0 (Antiviral Agents); 0 (Carbonic Anhydrase Inhibitors); 0 (Cholinergic Antagonists); 0 (Histamine Antagonists); 0 (Lubricant Eye Drops); 0 (Muscarinic Agonists); 0 (Muscarinic Antagonists); 0 (Ophthalmic Solutions); 0 (Prostaglandins, Synthetic)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  6 / 681 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28461266
[Au] Autor:Bao Q; Shen J; Jog R; Zhang C; Newman B; Wang Y; Choi S; Burgess DJ
[Ad] Endereço:University of Connecticut, School of Pharmacy, Storrs, CT 06269, United States.
[Ti] Título:In vitro release testing method development for ophthalmic ointments.
[So] Source:Int J Pharm;526(1-2):145-156, 2017 Jun 30.
[Is] ISSN:1873-3476
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:It is essential as well as challenging to develop a reliable in vitro release testing method for determining whether differences in release profiles exist between qualitatively and quantitatively equivalent ophthalmic ointment formulations. There is a lack of regulatory guidance on in vitro release testing methods for ophthalmic formulations. Three different in vitro release testing methods 1) USP apparatus 4 with semisolid adapters; 2) USP apparatus 2 with enhancer cells; and 3) Franz diffusion cells were investigated. Qualitatively and quantitatively equivalent ointments were prepared via hot melting and simple mixing methods using four different sources of excipients (i.e. white petrolatum). The ointment formulations were characterized for content uniformity, particle size, and rheological parameters. All the formulations showed adequate content uniformity and similar particle size. The ointments prepared via the hot melting processes showed higher rheological parameters, as did the ointments prepared using 'white' petrolatum that exhibited a yellowish color. The three in vitro release testing methods were compared and evaluated for reproducibility, discriminatory capability, and correlation with the rheological parameters. Compared with the compendial methods, the non-compendial method (Franz diffusion cells) showed poorer reproducibility. All three methods possessed the ability to discriminate between the ophthalmic ointments with manufacturing differences. However, the USP apparatus 4 method displayed the largest margin of discrimination between the release profiles of the different ophthalmic ointments. In addition, the in vitro release rate obtained using the USP apparatus 4 method showed the strongest logarithmic linear correlation with the rheological parameters (Power law consistency index (K value) and crossover modulus) compared to the other two methods.
[Mh] Termos MeSH primário: Administração Oftálmica
Liberação Controlada de Fármacos
Excipientes/química
Pomadas/análise
[Mh] Termos MeSH secundário: Química Farmacêutica
Tamanho da Partícula
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Excipients); 0 (Ointments)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  7 / 681 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29204644
[Au] Autor:Zhang X; Lin X; Liu Z; Wu Y; Yang Y; Ouyang W; Li W; Liu Z
[Ad] Endereço:Eye Institute of Xiamen University & Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Xiamen, Fujian, China.
[Ti] Título:Topical Application of Mizoribine Suppresses CD4+ T-cell-Mediated Pathogenesis in Murine Dry Eye.
[So] Source:Invest Ophthalmol Vis Sci;58(14):6056-6064, 2017 Dec 01.
[Is] ISSN:1552-5783
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose: We investigate the effect of topical application of mizoribine (MZR) eye drops on CD4+ T-cell-mediated immunity and epithelial damage in ocular surface of dry eye disease (DED). Methods: Topical application of MZR or vehicle eye drops was performed in mice subjected to desiccating stress (DS). The phenol red cotton test was used to measure tear production, and Oregon-green-dextran (OGD) staining was performed to assess corneal epithelial barrier function. PAS staining was used to quantify conjunctival goblet cells. Immunofluorescent staining and quantitative (q) RT-PCR were used to assess the expression of matrix metalloproteinase (MMP)-9 in corneal epithelium. qRT-PCR and ELISA were used to assess the production of TNF-α and IL-1ß in conjunctiva. Apoptosis in ocular surface was assessed by TUNEL and activation of caspase-8. CD4+ T-cell-mediated immunity was evaluated by CD4 immunohistochemistry and production of T helper cytokines, including IFN-γ, IL-13, and IL-17A in conjunctiva. Results: Compared to vehicle control mice, topical MZR-treated mice showed increased tear production, decreased goblet cell loss, and improved corneal barrier function. Topical application of MZR suppressed the expression of MMP-9 in corneal epithelium and apoptosis in ocular surface, while it had no obvious effect on production of TNF-α and IL-1ß in conjunctiva. Topical application of MZR decreased CD4+ T cells infiltration, with decreased production of IFN-γ and IL-17A, and increased production of IL-13 in conjunctiva. Conclusions: Topical application of MZR could alleviate epithelial damage and CD4+ T-cell-mediated immunity in ocular surface of DED.
[Mh] Termos MeSH primário: Linfócitos T CD4-Positivos/imunologia
Síndromes do Olho Seco/tratamento farmacológico
Imunidade Celular/efeitos dos fármacos
Ribonucleosídeos/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oftálmica
Animais
Apoptose
Linfócitos T CD4-Positivos/efeitos dos fármacos
Modelos Animais de Doenças
Síndromes do Olho Seco/imunologia
Síndromes do Olho Seco/patologia
Epitélio Anterior/efeitos dos fármacos
Epitélio Anterior/metabolismo
Epitélio Anterior/patologia
Feminino
Imuno-Histoquímica
Imunossupressores/administração & dosagem
Metaloproteinase 9 da Matriz/metabolismo
Camundongos
Camundongos Endogâmicos C57BL
Soluções Oftálmicas/administração & dosagem
Lágrimas/secreção
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunosuppressive Agents); 0 (Ophthalmic Solutions); 0 (Ribonucleosides); 4JR41A10VP (mizoribine); EC 3.4.24.35 (Matrix Metalloproteinase 9)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE
[do] DOI:10.1167/iovs.17-22852


  8 / 681 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28898355
[Au] Autor:Williams DL; Wirostko BM; Gum G; Mann BK
[Ad] Endereço:Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom.
[Ti] Título:Topical Cross-Linked HA-Based Hydrogel Accelerates Closure of Corneal Epithelial Defects and Repair of Stromal Ulceration in Companion Animals.
[So] Source:Invest Ophthalmol Vis Sci;58(11):4616-4622, 2017 Sep 01.
[Is] ISSN:1552-5783
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose: The purpose of this study was to determine the safety of topical ocular administration of a cross-linked, modified hyaluronic acid (xCMHA-S) hydrogel, and its effectiveness in accelerating repair and closure of acute and nonhealing corneal ulcers in companion animals as a veterinary treatment and its utility as a model for therapy in human corneal ulceration. Methods: Two concentrations of xCMHA-S (0.33% and 0.75%) were topically administered to the eyes of rabbits six times daily for 28 days to assess safety. Then, 30 dogs and 30 cats with spontaneous acute corneal ulcers were treated with either xCMHA-S (0.75%) or a non-cross-linked hyaluronic acid (HA) solution (n = 15 per group for each species), three times daily until the ulcer had healed. Finally, 25 dogs with persistent nonhealing corneal ulcers were treated with xCMHA-S (0.75%) twice daily until the ulcer had healed. Results: Both concentrations of the xCMHA-S hydrogel were well tolerated, safe, and nontoxic in the 28-day exaggerated dosing study in healthy rabbits. Topically applied xCMHA-S significantly accelerated closure of acute corneal stromal ulcers in dogs and cats compared with a non-cross-linked HA solution. Further, topical administration of the xCMHA-S aided in closure of nonhealing corneal stromal ulcers in dogs. Conclusions: Hyaluronic acid has previously been shown to aid in corneal wound repair. This study demonstrates that a cross-linked, modified HA hydrogel provides further benefit by accelerating time to corneal wound closure compared to a non-cross-linked HA solution in companion animals, and therefore may be beneficial in fulfilling an unmet need in humans.
[Mh] Termos MeSH primário: Doenças do Gato/tratamento farmacológico
Úlcera da Córnea/veterinária
Doenças do Cão/tratamento farmacológico
Ácido Hialurônico/análogos & derivados
[Mh] Termos MeSH secundário: Administração Oftálmica/veterinária
Animais
Gatos
Substância Própria/efeitos dos fármacos
Úlcera da Córnea/tratamento farmacológico
Cães
Epitélio Anterior/efeitos dos fármacos
Feminino
Ácido Hialurônico/administração & dosagem
Ácido Hialurônico/uso terapêutico
Hidrogéis/administração & dosagem
Hidrogéis/uso terapêutico
Masculino
Coelhos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hydrogels); 9004-61-9 (Hyaluronic Acid)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170913
[St] Status:MEDLINE
[do] DOI:10.1167/iovs.16-20848


  9 / 681 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28832741
[Au] Autor:Costa AXD; Gomes JÁP; Marculino LGC; Liendo VL; Barreiro TP; Santos MSD
[Ad] Endereço:Cornea and External Eye Disease Clinic, Departamento de Oftalmologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
[Ti] Título:Supratarsal injection of triamcinolone for severe vernal keratoconjunctivitis in children.
[So] Source:Arq Bras Oftalmol;80(3):186-188, 2017 Jun.
[Is] ISSN:1678-2925
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To evaluate the use of supratarsal injection of triamcinolone acetonide in severe vernal keratoconjunctivitis (VKC) in children. METHODS: Patients included in this open clinical trial were those with severe VKC-associated with keratitis, gelatinous limbal infiltrates, and/or giant papillae, with a history of recurrence and resistance to conventional topical antiallergic agents. Patients were treated with a supratarsal injection of 20 mg triamcinolone acetonide. RESULTS: Analysis included 27 injections in 23 eyes of 17 patients with severe allergic keratoconjunctivitis. Mean age was 12.3 (range: 7-19) years. Mean follow-up time was 39.3 months (SD=19.21). In the 17 patients, the disease was successfully controlled for an average of 3.6 months (range: 1-16), during which allergy symptoms and signs were significantly improved, with complete resolution of lid edema and conjunctival chemosis, significant decline of pannus and keratitis, and reduction of giant papillae size. CONCLUSION: Treatment of severe, acute VKC in children with supratarsal injection of 20 mg triamcinolone acetonide showed satisfactory results and was well tolerated by patients; it may therefore constitute a safe option for severe and challenging cases. While full disease remission was not achieved, a significant improvement was found in ocular allergy symptoms and signs, with a reduction in the frequency of acute recurrences.
[Mh] Termos MeSH primário: Conjuntivite Alérgica/tratamento farmacológico
Glucocorticoides/administração & dosagem
Injeções Intraoculares
Triancinolona Acetonida/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oftálmica
Adolescente
Idade de Início
Criança
Pálpebras/efeitos dos fármacos
Feminino
Seres Humanos
Masculino
Ilustração Médica
Estudos Prospectivos
Reprodutibilidade dos Testes
Fatores de Tempo
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); F446C597KA (Triamcinolone Acetonide)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE


  10 / 681 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28682887
[Au] Autor:Wang YR; Bian HL; Wang Q
[Ad] Endereço:aDepartment of Ophthalmology, The People's Hospital of Yan'an bDepartment of Ophthalmology, Affiliated Hospital of Yan'an University, Yan'an, China.
[Ti] Título:Atropine 0.5% eyedrops for the treatment of children with low myopia: A randomized controlled trial.
[So] Source:Medicine (Baltimore);96(27):e7371, 2017 Jul.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: This study aimed to assess the efficacy and safety of atropine 0.5% eyedrops (ATE) for the treatment of children with low myopia (LM). METHODS: In this study, a total of 126 children with LM were randomly divided into an intervention group (administered 0.5% ATE) and a control group (administered a placebo), with 63 children in each group. The outcome measurements were changes in the spherical equivalent (SE), and axial length (AL), as well as adverse events (AEs). RESULTS: Compared with placebo, administration of 0.5% ATE led to less progression in LM, as measured by SE, and less increase in AL (P < .01). In addition, no serious AEs occurred in both the groups. CONCLUSION: About 0.5% ATE was efficacious and safe for controlling myopia in children with LM.
[Mh] Termos MeSH primário: Atropina/administração & dosagem
Antagonistas Muscarínicos/administração & dosagem
Miopia/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Oftálmica
Atropina/efeitos adversos
Comprimento Axial do Olho/efeitos dos fármacos
Criança
Feminino
Seres Humanos
Masculino
Antagonistas Muscarínicos/efeitos adversos
Soluções Oftálmicas
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Muscarinic Antagonists); 0 (Ophthalmic Solutions); 7C0697DR9I (Atropine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170719
[Lr] Data última revisão:
170719
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170707
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007371



página 1 de 69 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde